Market Overview

Evecxia Inc. Appoints John Kaiser as Chief Executive Officer


Evecxia, Inc. today announced that its Board of Directors has appointed
John Kaiser as Chief Executive Officer (CEO) and interim Chairman of the
Board. Mr. Kaiser has been working with the company's management team
and Board since March 2018. He brings to Evecxia over three decades of
biopharmaceutical drug development and commercialization expertise
having most recently served as interim CEO of Cerecor Inc. Mr. Kaiser
also previously served as CEO of Denysias Bioscience, CBO at ACADIA
Pharmaceuticals and positions of increasing responsibilities over a 25+
year career at Eli Lilly and Company. Throughout his career, Mr. Kaiser
has demonstrated a track record of creating stakeholder value through
licensing & partnerships, operational efficiency, and commercial

"John brings invaluable experience to his new role as Evecxia's CEO from
many years in leading positions in both the pharma and biotech sectors,"
said Dr. Roger Jeffs, a member of Evecxia's Board of Directors and
co-founder of Bull City Select I, LLC, an early investor in Evecxia. Dr.
Jeffs continued, "John's leadership and operational capabilities will
immediately propel the growth of Evecxia as a clinical stage company. We
are delighted to have him in the CEO role."

John Kaiser added "Evecxia is poised to accelerate the development of
EVX-101, a clinical stage product candidate possessing a therapeutic
mechanism-of-action with human POC for efficacy and safety. EVX-101 is
exciting because risk is mitigated compared to novel, but unproven,
mechanisms and novel chemistry, and because of the tremendously large
unmet need that continues to exist for safe and effective adjunctive
antidepressants. I intend to leverage all of my experiences to build
upon the remarkable foundation created by founders Dr. Caron and Dr.
Jacobsen. And, I want to thank the Board for this appointment and am
excited to lead Evecxia toward improving lives, restoring hope."

About Evecxia

Evecxia is a privately funded, clinical stage pharmaceutical company
co-founded by Duke neuro-psychopharmacologists, Dr. Marc Caron and Dr.
Jacob Jacobsen. We are located in the Research Triangle Park, NC.
Evecxia's singular mission is to develop and commercialize EVX-101 to
treat patients suffering from disabling, common, and costly
neuropsychiatric conditions in which current therapies, in many cases,
are sub-optimal.

Evecxia is the first company dedicated to realizing the therapeutic
potential of 5-hydroxytryptophan via specialized Rx combinations and
drug delivery dosage forms.

About EVX-101

EVX-101 is a unique and proprietary oral slow-release formulation of
5-hydroxytryptophan (5-HTP) and low-dose carbidopa. Initially, EVX-101
will be developed and positioned as a first-line adjunctive treatment in
depressed patients responding inadequately to conventional
antidepressants. As an antidepressant, the development of EVX-101, a new
chemical entity (NCE), is uniquely de-risked because the therapeutic
mechanism—elevating extracellular serotonin beyond the effect of
conventional SSRI/SNRI antidepressants—enjoys human proof-of-concept
(POC) for efficacy and safety.

For more information about the Company and its product candidates,
please visit
or contact

View Comments and Join the Discussion!